STOCK TITAN

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Avadel Pharmaceuticals plc (AVDL) schedules conference call to discuss financial results for Q4 and full year 2023, along with a corporate update.
Positive
  • None.
Negative
  • None.

DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023.

Avadel plans to issue its Annual Report on Form 10-K for the year ended December 31, 2023, on Thursday, February 29.

A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Mogerley
Stern Investor Relations, Inc.
Courtney.Mogerley@sternir.com
(212) 698-8687

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162


Avadel Pharmaceuticals plc will host a conference call on Monday, March 4, 2024, at 7:30 a.m. ET.

The live audio webcast of the call can be accessed by visiting the investor relations section of Avadel Pharmaceuticals plc's website, www.avadel.com.

Avadel Pharmaceuticals plc plans to issue its Annual Report on Form 10-K on Thursday, February 29, 2024.

The replay of the webcast will be archived on Avadel Pharmaceuticals plc's website for 90 days following the event.

Participants are advised to register for the conference call at least 10 minutes prior to joining the call.
Avadel Pharmaceuticals plc

NASDAQ:AVDL

AVDL Rankings

AVDL Latest News

AVDL Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Medicinal and Botanical Manufacturing
Ireland
Dublin

About AVDL

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.